Completion of Acquisitions

Summary by AI ^BETAClose X

Light Science Technologies Holdings plc has successfully completed the acquisitions of RLUK Injection Ltd, including its subsidiary Injectaclad Ltd, the remaining 10% minority interest in UK Circuits and Electronics Solutions Limited, and the associated property, as previously announced on March 11, 2026. This strategic move integrates these entities into the Group, which focuses on innovative technology and manufacturing solutions for global food security and fire safety.

Disclaimer*

Light Science Tech. Holdings PLC

15 April 2026

Light Science Technologies Holdings plc

("LSTH", "Light Science", the "Company" or the "Group")

Completion of Acquisitions

Light Science Technologies Holdings plc (AIM: LST), the innovative technology and manufacturing business providing real-world solutions targeting issues including global food security and fire safety, is pleased to confirm that, further to its announcement on 11 March 2026, the acquisitions of RLUK Injection Ltd (including its wholly owned subsidiary Injectaclad Ltd), the remaining 10% minority interest in UK Circuits and Electronics Solutions Limited, and the related property have now completed.

For additional information please contact:

Light Science Technologies Holdings plc

Simon Deacon, Chief Executive Officer

Jim Snooks, Chief Financial Officer

Andrew Hempsall, Chief Operating Officer

www.lightsciencetechnologiesholdings.com

via Walbrook PR

Shore Capital (Nominated Adviser and Broker)

Stephane Auton / George Payne

+44 (0)20 7408 4050

Walbrook PR Ltd (Media & Investor Relations)

Nick Rome / Marcus Ulker

Tel: +44 (0)20 7933 8780 or lst@walbrookpr.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END